News | Blood Testing | September 04, 2018

AI-Driven Blood Test Accurately Diagnoses Peripheral Artery Disease in Diabetic Patients

Prevencio’s multi-protein, AI-driven HART PAD biomarker test has potential to improve clinical outcomes and reduce costs in the treatment of diabetic patients

AI-Driven Blood Test Accurately Diagnoses Peripheral Artery Disease in Diabetic Patient

September 4, 2018 — Prevencio Inc. announced new data demonstrating its HART PAD test accurately diagnoses peripheral artery disease (PAD) in diabetes mellitus (DM) patients, a patient population in which PAD prevalence has traditionally been difficult to assess. Researchers believe these findings, presented at the 2018 European Society of Cardiology (ESC) Congress, Aug. 25-28 in Munich, Germany, could lead to early identification of PAD and improve patient clinical outcomes, as well as prevent patients without PAD from undergoing unnecessary, expensive and invasive tests.

The study is follow-on to data presented at the American Diabetes Association (ADA) 2018 Scientific Sessions in June demonstrating Prevencio’s HART CAD and HART CVE tests accurately diagnose coronary artery disease (CAD) and predict the risk for major adverse cardiac events (MACE) in DM patients. Similar to CAD, PAD is commonly due to atherosclerosis, a plaque buildup in the arteries which restricts blood flow.

In this study, researchers assessed the company’s artificial intelligence (AI)-driven HART PAD diagnostic test on patients enrolled in Massachusetts General Hospital’s (MGH) Catheter Sampled Blood Archive in Cardiovascular Disease (CASABLANCA) study. The HART PAD test algorithmically assesses six biomarkers linked to atherosclerosis, as well as a patient’s history of hypertension. In patients with DM, the HART PAD panel had excellent performance for diagnosis of PAD. Using a five-point score, a score of 1 had a 100 percent negative predictive value (NPV) and a score of 5 had a 95 percent positive predictive value (PPV). Additionally, the HART PAD panel was highly accurate in predicting the need for revascularization in patients with PAD. These results were comparable to those patients without DM.

Principal investigator James L. Januzzi, M.D., practicing cardiologist at MGH and professor of medicine at Harvard Medical School, said, “The HART PAD test may allow for the diagnosis and treatment of many more patients with currently undetected PAD. In the clinical setting, these findings could assist physicians to identify peripheral artery disease earlier, provide guideline-recommended care and monitor at-risk patients for vascular complications. We believe HART tests could also play an important role in identifying high-risk patients for enrollment in clinical trials, thereby saving time and lowering overall trial costs.”

PAD affects more than 202 million people worldwide and is often underdiagnosed and undertreated until the disease has reached advanced stages. Patients with DM are at substantial risk of developing PAD. Patients with PAD have increased risk of CAD, heart attack or stroke and, if left untreated, PAD can lead to foot or leg amputation.

For more information: www.prevenciomed.com

Related Content

New Regulatory Approvals Driving Research and Development Dollars in Medical Imaging Artificial Intelligence
News | Artificial Intelligence | August 01, 2018
Medical imaging has become the bellwether for the application of artificial intelligence (AI) technologies, especially...
Videos | Artificial Intelligence | July 10, 2018
Partho Sengupta, M.D., DM, FACC, FASE, chief division of cardiology, director of cardiac imaging, West Virginia Unive
Northwestern Medicine Bluhm Cardiovascular Institute Announces Launch of Artificial Intelligence Center
News | Artificial Intelligence | June 26, 2018
Northwestern Medicine Bluhm Cardiovascular Institute in Illinois received a $25 million gift from the Bluhm Family...
EnvoyAI, TeraRecon and Insignia Bringing Artificial Intelligence to U.K. Customers
Technology | Artificial Intelligence | May 11, 2018
EnvoyAI announced a new integration with Insignia Medical Systems’ InSight PACS (picture archiving and communication...
Charles E. Kahn Jr. Named Editor of Radiology: Artificial Intelligence
News | Artificial Intelligence | May 02, 2018
May 2, 2018 – The Board of Directors of the Radiological Society of North America (RSNA) announced that Charles E.
Philips Launches HealthSuite Insights AI Platform for Healthcare
Technology | Artificial Intelligence | March 19, 2018
March 19, 2018 — Philips recently announced the launch of HealthSuite Insights, including the Insights Marketplace, t
Aidoc Introduces AI Solution for Whole-Body CT Scan Analysis
News | Artificial Intelligence | February 20, 2018
Deep learning startup company Aidoc announced what it calls the world’s first and only comprehensive, full-body...
GE and NVIDIA Unveil Artificial Intelligence Upgrades to CT, Ultrasound and Analytics Solutions
Technology | Artificial Intelligence | December 14, 2017
At the 2017 Radiological Society of North America (RSNA) Annual Meeting, GE Healthcare and NVIDIA announced a series of...
Fujifilm Introduces Artificial Intelligence Initiative for U.S. Market at RSNA 2017
News | Artificial Intelligence | December 04, 2017
Fujifilm Medical Systems U.S.A. Inc. announced the expansion of the company's artificial intelligence (AI) development...
Xavier University Announces Healthcare Artificial Intelligence Summit
News | Artificial Intelligence | August 07, 2017
Xavier University has launched the Xavier Center for Artificial Intelligence (AI), a pioneering effort to accelerate...
Overlay Init